Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
Healthcare
$3.28 +0.00%
+$0.00 today
- Market cap
- $571.17M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
52W Low $0.91High $3.22
Volume 0.23M
Average 0.16M
Balance Sheet
Inspect the capital base behind the business.
Assets
$15.99M
FY 2025 · Annual
+70.3% YoYLiabilities
$2.89M
FY 2025 · Annual
+120.8% YoYEquity
$13.10M
FY 2025 · Annual
+62.1% YoYBalance Sheet
USD
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $4.1M |
| Other Current | $8.4M |
| Total Current Assets | $12.5M |
| PP&E (Net) | $540.0K |
| Other Non-current | $96.0K |
| Total Non-current Assets | $636.0K |
| Total Assets | $13.1M |
Analysis
Selected assets total $13.1M for Latest. The largest visible component is Other Current at $8.4M, about 63.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 6, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| SC 13G | SC 13G filing | Oct 30, 2026 | |
| 8-K | Current report | Oct 27, 2026 |
How much cash does ENTX have?
Entera Bio Ltd. (ENTX) reported $7.11M in cash and equivalents in fiscal 2025.
How much debt does ENTX carry?
Entera Bio Ltd. (ENTX) reported $490,000.00 of total debt, with net debt of -$6.62M.
Continue the stock analysis
Jump to another research area for this company.